Holen Sie sich die Stockscreener-App
3.76
6.82%
0.24
Handel nachbörslich:
3.76
Schlusskurs vom Vortag:
$3.52
Offen:
$3.46
24-Stunden-Volumen:
283.88K
Relative Volume:
1.46
Marktkapitalisierung:
$120.95M
Einnahmen:
$4.06M
Nettoeinkommen (Verlust:
$-50.22M
KGV:
-2.3231
EPS:
-1.6185
Netto-Cashflow:
$-25.37M
1W Leistung:
-2.08%
1M Leistung:
-6.00%
6M Leistung:
-43.29%
1J Leistung:
+0.00%
1-Tages-Spanne:
$3.46
$3.97
1-Wochen-Bereich:
$3.27
$4.55
52-Wochen-Spanne:
$2.33
$8.51
Insight Molecular Diagnostics Inc Stock (IMDX) Company Profile
Firmenname
Insight Molecular Diagnostics Inc
Sektor
Branche
Telefon
949-409-7600
Adresse
2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE
Compare IMDX vs TMO, DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMDX
Insight Molecular Diagnostics Inc
|
3.76 | 120.95M | 4.06M | -50.22M | -25.37M | -1.6185 |
TMO
Thermo Fisher Scientific Inc
|
469.71 | 174.55B | 45.20B | 6.88B | 6.75B | 18.19 |
DHR
Danaher Corp
|
177.25 | 125.45B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
565.93 | 44.95B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
115.55 | 32.65B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
309.87 | 30.42B | 3.17B | 642.63M | 516.49M | 10.77 |
Insight Molecular Diagnostics Inc Stock (IMDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-28 | Eingeleitet | Lake Street | Buy |
| 2022-05-24 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2022-03-14 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2022-01-07 | Eingeleitet | Stephens | Overweight |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-03-17 | Fortgesetzt | Needham | Buy |
| 2021-01-07 | Hochstufung | The Benchmark Company | Speculative Buy → Buy |
| 2020-12-16 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-11-30 | Eingeleitet | BTIG Research | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2020-07-30 | Bestätigt | The Benchmark Company | Speculative Buy |
| 2020-07-01 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-06-30 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2020-06-02 | Eingeleitet | Needham | Buy |
| 2019-02-13 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-01-29 | Hochstufung | Janney | Neutral → Buy |
| 2018-12-19 | Fortgesetzt | Lake Street | Buy |
Alle ansehen
Insight Molecular Diagnostics Inc Aktie (IMDX) Neueste Nachrichten
Major Investor Makes Bold Move Into Insight Molecular Diagnostics - TipRanks
Broadwood Partners buys $652,875 in Insight Molecular Diagnostics By Investing.com - Investing.com South Africa
Broadwood Partners buys $652,875 in Insight Molecular Diagnostics - Investing.com
Broadwood boosts Insight Molecular (IMDX) stake with 182,861-share buy - Stock Titan
Insight (IMDX) Stock Range-Bound (Marginal Loss) 2026-04-20Gap Down Stocks - Cổng thông tin điện tử tỉnh Tây Ninh
Needham Maintains Insight Molecular Diagnostics(IMDX.US) With Buy Rating, Maintains Target Price $9 - 富途牛牛
Stock List: Research Stocks from Around the World - GuruFocus
IMDX: GraftAssure's decentralized PCR test drives transplant diagnostics innovation and market expansion - TradingView
IMDX: GraftAssure aims to transform transplant diagnostics with decentralized, high-margin testing - TradingView — Track All Markets
Real-World Evidence and Industry Momentum Builds for iMDx's Flagship GraftAssure Assay - marketscreener.com
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Real-World Evidence and Industry Momentum Builds for iMDx’s Flagship GraftAssure Assay - GlobeNewswire
Kidney transplant test data heads to 3 global medical meetings - Stock Titan
Why The Insight Molecular Diagnostics (IMDX) Story Is Shifting After Cash Raise And FDA Catalyst - Yahoo Finance
IMDX Options Volatility — NASDAQ:IMDX - TradingView
IMDX Options Chain — NASDAQ:IMDX - TradingView
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Capital expenditures of Insight Molecular Diagnostics Inc. – NASDAQ:IMDX - TradingView
IMDX Technical Analysis & Stock Price Forecast - Intellectia AI
Insight Molecular Diagnostics Inc. Stock Forecast Summary - Meyka
BTIG reiterates Neutral rating on Insight Molecular stock By Investing.com - Investing.com Canada
BTIG reiterates Neutral rating on Insight Molecular stock - Investing.com
Insight Molecular (IMDX) Soars 22.36% During Intraday Rally — What’s Driving the Market Turbulence? - Bitget
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
IMDX CFO’s RSUs Vest as Company Withholds Shares for Taxes - Stock Titan
IMDX (IMDX) VP Yang sees RSUs vest while shares withheld for taxes - Stock Titan
CEO at Insight Molecular (IMDX) vests 47,170 RSUs with no share sale - Stock Titan
Insight Molecular Diagnostics Inc (OCX) Stock Price Quote Today & Current Price Chart - Capital.com
Trade Insight Molecular Diagnostics IncOCX CFD - Capital.com
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
How The Insight Molecular Diagnostics (IMDX) Story Is Shifting With New Funding And FDA Catalyst - Yahoo! Finance Canada
Insight Molecular Diagnostics Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Needham reiterates Buy on Insight Molecular stock, $9 target By Investing.com - Investing.com India
Insight Molecular Diagnostics Inc. Q4 2025 earnings preview - MSN
Needham reiterates Buy on Insight Molecular stock, $9 target - Investing.com
Insight Molecular Diagnostics outlines $2B annual market opportunity and signals rapid commercialization push for GraftAssureDx - MSN
Earnings call transcript: Insight Molecular Diagnostics Q4 2025 reveals strategic milestones - Investing.com India
Insight Molecular Diagnostics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Insight Molecular Diagnostics (NASDAQ:IMDX) Soars on 285% Revenue Beat and Key FDA Submission - ChartMill
Insight Molecular Diagnostics: Q4 Earnings Snapshot - crossville-chronicle.com
IMDX: Revenue doubled and net loss narrowed as focus shifted to transplant diagnostics and kit commercialization - TradingView
IMDX: FDA submission of GraftAssureDx and strong clinical data set stage for 2026 commercialization - TradingView
IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 Results - The Manila Times
Insight Molecular 2025 10-K: Revenue $4.06M, Net Loss $50.22M - TradingView
Insight Molecular Diagnostics posts Q4 2025 results; revenue $1.1M in quarter, $4.1M full year - TradingView
Insight Molecular Diagnostics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - MarketScreener
Insight Molecular Diagnostics (IMDX) files GraftAssureDx with FDA and reports 2025 loss - Stock Titan
Finanzdaten der Insight Molecular Diagnostics Inc-Aktie (IMDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.42%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):